Back to search
FDAFDA · Food and drugs·Recall number Z-0669-2020

Elecsys Anti-HAV IgM assay-for the in vitro qualitative detection of IgM antibodies to hepatitis A virus (anti-HAV IgM) in human serum and plasma Catalog number: 07026773190

Published December 18, 2019 · Recall initiated: October 28, 2019

Summary

FDA records medical device Class II recall Z-0669-2020, published December 18, 2019 and initiated October 28, 2019. Recalling firm: Roche Diagnostics Operations, Inc.; Status: Terminated; Reported quantity: 712 units; Lot: Anti-HAV IgM APP-file (version 06.05-101). Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Current software version of the Anti-HAV IgM APP-file (version 06.05-101) downloaded an erroneous Border Area setting, (1.0 1.00) instead of (0.90 1.10).

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Roche Diagnostics Operations, Inc.
Distributor
US Nationwide distribution.
Lot
Anti-HAV IgM APP-file (version 06.05-101)
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Elecsys Anti-HAV IgM assay-for the in vitro qualitative detection of IgM antibodies to hepatitis A virus (anti-HAV IgM) in human serum and plasma Catalog number: 07026773190 recalled?

Yes. FDA published recall Z-0669-2020 on December 18, 2019. Reported hazard: Current software version of the Anti-HAV IgM APP-file (version 06.05-101) downloaded an erroneous Border Area setting, (1.0 1.00) instead of (0.90 1.10).

What should I do if I have this product?

Voluntary: Firm initiated · Letter